Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Cyteir Therapeutics
Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq
March 07, 2024
From
Cyteir Therapeutics
Via
Business Wire
Tickers
CYT
Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile
October 12, 2023
From
Cyteir Therapeutics
Via
Business Wire
Tickers
CYT
Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution
June 30, 2023
From
Cyteir Therapeutics
Via
Business Wire
Tickers
CYT
Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile
June 03, 2023
From
Cyteir Therapeutics
Via
Business Wire
Tickers
CYT
Cyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
March 23, 2023
From
Cyteir Therapeutics
Via
Business Wire
Tickers
CYT
Cyteir Therapeutics Promotes David Gaiero to Chief Financial Officer
February 06, 2023
From
Cyteir Therapeutics
Via
Business Wire
Tickers
CYT
Cyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash Runway
January 19, 2023
From
Cyteir Therapeutics
Via
Business Wire
Tickers
CYT
Cyteir Therapeutics Reports Third Quarter 2022 Financial Results and Operational Highlights
November 07, 2022
From
Cyteir Therapeutics
Via
Business Wire
Tickers
CYT
Cyteir Therapeutics Presents Poster on the Identification of Mechanism of Action of CYT-0851 at the 34th Annual EORTC-NCI-AACR Symposium
October 12, 2022
From
Cyteir Therapeutics
Via
Business Wire
Tickers
CYT
Cyteir Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
August 31, 2022
From
Cyteir Therapeutics
Via
Business Wire
Tickers
CYT
Cyteir Therapeutics Reports Second Quarter 2022 Financial Results and Operational Highlights
August 08, 2022
From
Cyteir Therapeutics
Via
Business Wire
Tickers
CYT
Cyteir Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference
August 01, 2022
From
Cyteir Therapeutics
Via
Business Wire
Tickers
CYT
CYT-0851 Phase 1 Dose Escalation Results Show Early Clinical Activity and Generally Well Tolerated Safety Profile in Advanced Solid Tumors and Hematologic Malignancies
June 05, 2022
From
Cyteir Therapeutics
Via
Business Wire
Tickers
CYT
Cyteir Therapeutics to Participate in the 2022 Jefferies Healthcare Conference
May 31, 2022
From
Cyteir Therapeutics
Via
Business Wire
Tickers
CYT
Cyteir Therapeutics Reports First Quarter 2022 Financial Results and Operational Highlights
May 05, 2022
From
Cyteir Therapeutics
Via
Business Wire
Tickers
CYT
Cyteir Therapeutics to Participate in the 2022 Bank of America Healthcare Conference
May 04, 2022
From
Cyteir Therapeutics
Via
Business Wire
Tickers
CYT
Cyteir Therapeutics Names Krisztina Nemenyi as Senior Vice President of Regulatory Affairs and Quality
May 03, 2022
From
Cyteir Therapeutics
Via
Business Wire
Tickers
CYT
Cyteir Therapeutics Names Adam Veness General Counsel
April 25, 2022
From
Cyteir Therapeutics
Via
Business Wire
Tickers
CYT
Cyteir Therapeutics to Host Virtual Research and Development (R&D) Day on April 26, 2022
April 18, 2022
From
Cyteir Therapeutics
Via
Business Wire
Tickers
CYT
Cyteir Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
March 16, 2022
From
Cyteir Therapeutics
Via
Business Wire
Tickers
CYT
Cyteir Therapeutics Announces the Appointment of Stephen Sands to Board of Directors
February 24, 2022
From
Cyteir Therapeutics
Via
Business Wire
Tickers
CYT
Cyteir Therapeutics Announces First Patient Dosed in Phase 2 with CYT-0851
February 08, 2022
From
Cyteir Therapeutics
Via
Business Wire
Tickers
CYT
Cyteir Therapeutics Announces the Appointment of John F. Thero to Board of Directors
February 07, 2022
From
Cyteir Therapeutics
Via
Business Wire
Tickers
CYT
Cyteir Therapeutics Announces First Patient Dosed in Phase 1 Combination Trial With CYT-0851
January 12, 2022
From
Cyteir Therapeutics
Via
Business Wire
Tickers
CYT
Cyteir Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare Conference
January 03, 2022
From
Cyteir Therapeutics
Via
Business Wire
Tickers
CYT
Cyteir Therapeutics Announces the Appointment of Dr. Jeffrey S. Humphrey to Board of Directors
December 16, 2021
From
Cyteir Therapeutics
Via
Business Wire
Tickers
CYT
Cyteir Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights
November 12, 2021
From
Cyteir Therapeutics
Via
Business Wire
Tickers
CYT
Cyteir Therapeutics to Participate in the Credit Suisse 30th Annual Healthcare Conference
November 01, 2021
From
Cyteir Therapeutics
Via
Business Wire
Tickers
CYT
Cyteir Therapeutics Selected to Join Russell 2000® Index
September 20, 2021
From
Cyteir Therapeutics
Via
Business Wire
Tickers
CYT
Cyteir Therapeutics to Participate in the 19th Annual Morgan Stanley Global Healthcare Conference
September 01, 2021
From
Cyteir Therapeutics
Via
Business Wire
Tickers
CYT
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.